Nguyen, Thao Thi Thanh
Shingyoji, Masato
Hanazono, Michiko
Zhong, Boya
Morinaga, Takao
Tada, Yuji
Shimada, Hideaki
Hiroshima, Kenzo
Tagawa, Masatoshi http://orcid.org/0000-0003-2906-1555
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (16K21639, 16K09598, 17K10617)
Article History
Received: 24 September 2020
Revised: 7 June 2021
Accepted: 8 June 2021
First Online: 2 July 2021
Competing interests
: The authors declare that there is no conflict of interests in this research. We obtained a grant from Nichias Corporation. It is not a pharmaceutical company but a company making industrial products for building, automobiles and pipes (see ExternalRef removed). The grant is as a kind of their mécénat activities, corporate social contributions, which is aimed to assist for medical research for intractable cancer treatments. We are thereby irrelevant to any employment, consultancy, patents or products in development or marketed products to the company.
: This study was approved by the Institutional Ethical Committee and Recombinant DNA committee of Chiba Cancer Center Research Institute and Chiba University (Gene 1–2 and 1–3), and was conducted according to conditions for the use of living modified organisms by Biosafety Regulations in Japan. The animal experiments were approved by the animal experiment and welfare committee of Chiba Cancer Center Research Institute (16-1) and Chiba University (2-302), and were performed according to the guideline on the animal experiments.